Diabetic Nephropathy Modeling in Rodent Systems

Diabetic nephropathy is a leading cause of chronic kidney disease and end-stage renal failure in people with type 1 and type 2 diabetes. Rodent systems—including mice and rats—have been instrumental in dissecting the molecular mechanisms of hyperglycaemia-driven renal injury, from early glomerular hyperfiltration and albuminuria through mesangial expansion, basement membrane thickening and eventual tubulointerstitial fibrosis. Models range from chemically induced diabetes, most commonly via streptozotocin administration, to spontaneous genetic strains such as the leptin-deficient ob/ob or Leprdb/db mice, and designer transgenic or knockout lines combining diabetic susceptibility with pro-fibrotic or hypertensive backgrounds. These approaches permit controlled exploration of pathogenic pathways, the testing of anti-diabetic and renoprotective compounds, and the identification of biomarkers relevant to human disease progression. However, no single rodent model fully recapitulates the complexity of human diabetic nephropathy, and differences in strain susceptibility, intervention timing and endpoints necessitate careful experimental design. Ongoing refinements in genetic engineering, long-term insulin supplementation protocols and advanced imaging are enhancing the translational relevance of these preclinical systems, offering vital insights into disease mechanisms and therapeutic targets on a global scale.

Research from Nature Portfolio

Recent studies using the Leprdb/db mouse model have shown that administration of the acetylcholinesterase inhibitor galantamine not only improves systemic glycaemic control—evidenced by lower fasting blood glucose, HbA1c and improved insulin sensitivity indices—but also attenuates renal injury. Treated animals exhibit reduced albuminuria, preservation of glomerular architecture and diminished activation of inflammatory and apoptotic pathways in the kidney, linked to modulation of the glucagon-like peptide-1 axis and downregulation of p38 MAPK and SGLT-2 expression. In a complementary approach, combining low-dose streptozotocin with unilateral nephrectomy in a commonly used mouse strain overcame its inherent resistance to diabetic kidney damage. This dual intervention reliably induced hyperglycaemia, albuminuria and characteristic histopathological lesions—including mesangial expansion and basement membrane thickening—within a relatively short timeframe, providing a robust platform for evaluating novel therapeutics targeting type 1 diabetes–associated nephropathy.

Diabetic Nephropathy Modeling in Rodent Systems publication trend

The graph below shows the total number of articles in diabetic nephropathy modeling in rodent systems across all publications each year (not limited to Nature Index journals).

Technical terms

Albuminuria: The abnormal excretion of albumin in urine, indicative of glomerular filtration barrier damage.

Glomerulosclerosis: Scarring or hardening of the glomeruli, a hallmark of progressive renal injury.

Streptozotocin: A chemical agent used to induce pancreatic beta-cell destruction and hyperglycaemia in rodents.

Leprdb/db mouse: A genetic model of type 2 diabetes carrying a mutation in the leptin receptor, predisposed to obesity and nephropathy.

Unilateral nephrectomy: Surgical removal of one kidney, often performed to accelerate renal injury in experimental models.

References

1. Experimental Models to Study Diabetes Mellitus and Its Complications: Limitations and New Opportunities. International Journal of Molecular Sciences (2023).
2. Galantamine improves glycemic control and diabetic nephropathy in Leprdb/db mice. Scientific Reports (2023).
3. Super-Resolution Ultrasound Imaging of Renal Vascular Alterations in Zucker Diabetic Fatty Rats during the Development of Diabetic Kidney Disease. Diagnostics (2023).
4. Combining streptozotocin and unilateral nephrectomy is an effective method for inducing experimental diabetic nephropathy in the ‘resistant’ C57Bl/6J mouse strain. Scientific Reports (2018).